Here’s your news in brief: FDA approved new, lower-dose formulations of two products last week, Adapt Pharma Ltd.'s emergency nasal spray opioid overdose treatment Narcan and Ironwood Pharmaceuticals Inc. and Allergan PLC's Linzess for chronic idiopathic constipation.
The agency also accepted Genentech Inc.'s application for a new indication for Actemra to treat giant cell arteritis (GCA)....





